Get started
Author

Aimin Zang

Observed names: A M Zang, A. Zang, Ai-min Zang, AiMin Zang
ORCID: 0000-0001-6777-1959
Observed ORCID: 0000-0001-6777-1959
OpenAlex ID: A5080081094
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
2023 · Jianming Xu, Haiping Jiang, et al. · JAMA · 451
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
2022 · Yuankai Shi, Gongyan Chen, et al. · The Lancet Respiratory Medicine · 245
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
2024 · Aditya Bardia, Komal Jhaveri, et al. · Journal of Clinical Oncology · 237
PDF
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
2024 · Zefei Jiang, Quchang Ouyang, et al. · Nature Medicine · 145
Circular RNA: Biogenesis, Degradation, Functions and Potential Roles in Mediating Resistance to Anticarcinogens
2019 · Xiuchao Geng, Youchao Jia, et al. · Epigenomics · 126
PDF
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
2025 · Lin Shen, Yanqiao Zhang, et al. · Nature Medicine · 118
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
2023 · Shun Lu, Jianying Zhou, et al. · The Lancet Respiratory Medicine · 81
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study
2022 · Yuankai Shi, Gongyan Chen, et al. · Journal of Thoracic Oncology · 79
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
2023 · Yuanyuan Zhao, Yuxiang Ma, et al. · Journal of Hematology & Oncology · 71
PDF
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
2023 · Yongfeng Yu, Jianya Zhou, et al. · EClinicalMedicine · 68
Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
2021 · Chun Han, Sisi Ye, et al. · Frontiers in Oncology · 68
PDF
Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study
2021 · Ningjing Lin, Mingzhi Zhang, et al. · European Journal of Cancer · 50
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer
2025 · Xichun Hu, Qingyuan Zhang, et al. · Signal Transduction and Targeted Therapy · 42
PDF
FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis
2020 · Hua Yang, Lili Ren, et al. · Cell Death and Disease · 41
PDF
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib
2020 · Yanhong Shang, Xiaofang Li, et al. · Scientific Reports · 37
PDF
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study
2022 · Yuankai Shi, Baolan Li, et al. · Journal of Thoracic Oncology · 36
PDF
Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer
2020 · Zhiyu Wang, Aimin Zang, et al. · Drug Design Development and Therapy · 35
PDF
Colorectal cancer combination therapy using drug and gene co-delivered, targeted poly(ethylene glycol)-ε-poly(caprolactone) nanocarriers
2018 · Zhiyu Wang, Yaning Wei, et al. · Drug Design Development and Therapy · 34
PDF
Defect-Related Luminescent Mesoporous Silica Nanoparticles Employed for Novel Detectable Nanocarrier
2015 · Kun Ge, Cuimiao Zhang, et al. · ACS Applied Materials & Interfaces · 30
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
2022 · Shun Lu, Yiping Zhang, et al. · Journal of Thoracic Oncology · 29
PDF
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors
2024 · Jian Li, Ye Xu, et al. · Chinese Journal of Cancer Research · 21
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
2022 · Guanghui Gao, Jian Ni, et al. · Translational Lung Cancer Research · 21
PDF
The interleukin-18 gene promoter -607 A/C polymorphism contributes to non-small-cell lung cancer risk in a Chinese population
2016 · Youchao Jia, Aimin Zang, et al. · OncoTargets and Therapy · 20
PDF
Cancer biomarkers discovered using pan-cancer plasma proteomic profiling
2025 · Lin Bai, Jiacheng Lyu, et al. · Nature Biomedical Engineering · 19
Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy
2024 · Jiacheng Lyu, Lin Bai, et al. · Nature Communications · 19
Works count: 82
Citation count: 2,304
H-index: 21
I10-index: 32
Year
Topic
Type